Floatz logo

LAVENDER OIL

Non-Melanoma Skin Cancer

San Gallicano Dermatological Institute IRCCSmixtureN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

39 Active assets in the Non-Melanoma Skin Cancer cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
University of Alabama at Birmingham
Phase 4BB
Pembrolizumab
Essen Biotech
Phase 2BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
gsk1120212
Cancer Research UK
Phase 2/3B
Nivolumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B

View all 50 →

Same molecule, other indications

LAVENDER OIL is also rated in:

urinary bladder, atony ofDormant
D
Indicative ·
30 / 100
View asset →
Urinary Incontinence (UI)Dormant
D
Indicative ·
30 / 100
View asset →
multiple sclerosisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →